Logotype for Quanterix Corporation

Quanterix (QTRX) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Quanterix Corporation

Q3 2026 earnings summary

9 Nov, 2026

Executive summary

  • Q3 revenue was $34.974M, up 6.3% sequentially but down 13.1% YoY; management characterized the quarter as an initial step toward restoring growth.

  • Commercial and product strategy changes began supporting Q3 revenue; management expects improvement in Q4 and continued growth in 2027.

  • LucentAD test volume more than doubled sequentially, spatial consumables neared a record, and Accelerator Lab bookings rose for a second consecutive quarter.

Financial highlights

  • Q3 revenue was $34.974M versus $40.233M in Q3 2025; adjusted pro forma decline was 8.6%, excluding $2.4M from a terminated program and adding $0.6M of Akoya pre-acquisition revenue to the comparison.

  • Nine-month revenue rose 10% to $104.3M from $95.0M; product revenue increased 16% to $74.1M, while service and other revenue declined 4% to $28.8M.

  • Q3 GAAP gross profit was $13.5M; non-GAAP gross profit was $16.6M. GAAP operating loss was $22.5M versus $37.3M, and adjusted operating loss was $18.9M versus $19.8M.

  • Net loss was $21.6M versus $33.5M; adjusted EBITDA loss was $12.2M versus $11.9M.

  • Non-GAAP operating expenses were $35.4M, down $2.8M YoY and up $3.7M QoQ, including a one-time compensation timing impact; GAAP operating expenses were $36.0M, down $27.2M YoY.

Outlook and guidance

  • FY2026 revenue guidance narrowed to $142M–$146M; adjusted gross margin guidance remains 48%–50%.

  • Year-end 2026 cash guidance is $70M, with no debt; Q3 ended with $80.7M in cash, cash equivalents, marketable securities and restricted cash.

  • Commercial initiatives are expected to begin lifting revenue in Q4, contribute more materially in 2027 and beyond, and support the unchanged 2027 cash-flow breakeven target.

  • Q4 growth drivers include Accelerator bookings, instrument placements and consumables; bookings typically convert to billings in four to six months.

  • Operating losses and negative operating cash flows are expected to continue into 2027; planned spending includes R&D, diagnostics, regulatory submissions and systems enhancements.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Quanterix